| Drug Name: | Carbidopa (28860-95-9) |
|---|---|
| PubChem ID: | 34359 |
| SMILES: | C[C@](CC1=CC(=C(C=C1)O)O)(C(=O)O)NN |
| InchiKey: | TZFNLOMSOLWIDK-JTQLQIEISA-N |
| Therapeutic Category: |
| Molecular Weight (dalton) | : | 226.232 |
| LogP | : | -0.0531 |
| Ring Count | : | 1 |
| Hydrogen Bond Acceptor Count | : | 5 |
| Hydrogen Bond Donor Count | : | 5 |
| Total Polar Surface Area | : | 115.81 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|---|---|---|---|
| Spiramycin (24916-50-5) | Reduces The Antiparkinsonian Effects | Antagonistic | spiramycin markedly reduces the absorption of carbidopa, possibly by forming a non-absorbable complex in the gut or by accelerating its transit through the gut | Effect of a macrolide (spiramycin) on the pharmacokinetics of L-dopa and carbidopa in healthy volunteers |
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category